Day TwoWednesday, 25 March 2026 - Western European Summer Time (WEST)

The biotech industry stands at an exciting crossroads, where scientific innovation—from gene editing to AI-driven drug discovery—is advancing at an unprecedented pace. While the funding landscape has evolved following the pandemic-driven biotech boom of 2020-2021, this shift presents a unique opportunity to rethink and refine traditional funding models. Investors are increasingly focused on de-risked assets with clear clinical and commercial pathways, creating a fertile environment for companies to differentiate themselves and explore new avenues for growth. This panel will bring together visionary leaders to discuss how the biotech ecosystem can adapt and thrive in this dynamic environment. By embracing strategic innovation and collaboration, the industry has the potential to unlock sustainable funding mechanisms that will propel breakthrough technologies forward and ensure long-term success.

• How can early-stage biotechs stand out in a competitive landscape and attract capital?
• Should companies consider staying private longer, or are public markets still a viable option for growth?
• What innovative funding and collaboration models—such as venture creation or corporate spinouts—can drive the next wave of biotech success?

M&A has long been a cornerstone of growth and innovation in the biopharma industry, serving as a vital mechanism for recycling capital, fostering collaboration, and accelerating the development of transformative therapies. As the sector continues to evolve, strategic M&A has the potential to act as a powerful catalyst for revitalizing the biopharma ecosystem, driving growth, and boosting investor confidence. This panel will explore how both large pharma and biotech companies can leverage M&A to unlock new opportunities, scale breakthrough innovations, and create momentum that propels the industry forward.

• What barriers are preventing large pharma from engaging in more M&A, and how can they be addressed?
• How can biotech companies make themselves more attractive acquisition targets in a selective market?
• What types of deals are most likely to drive sector momentum?